JANUS HENDERSON GROUP PLC

10% owner Janus Henderson buys 5,818 shares of ABIO at $2.93–$2.98 for $17,066.77; extends recent buying pattern

Janus Henderson, a 10% owner, completed 2 separate purchases totaling 5,818 shares (5.8K shares) for $17,066.77 on 2024-08-16 at prices of $2.93 and $2.98 per share, raising its post-transaction holdings to 2,117,213 shares (2.12M shares). This buy follows four prior purchases at the same ticker within the preceding 3 weeks (2024-07-24 and 2024-07-25), with only one of those five recent same-ticker trades measurable at 90 days and showing a +876.9% return. The current stock price of $44.04 is 30-day +11.7% and 90-day +12.9%, a substantial appreciation from the $2.93–$2.98 transaction prices. However, the company remains unprofitable with net income of $-2,678,000 and $0.00 in latest-quarter revenue, and Janus Henderson's cross-ticker track record shows its 13 prior buys averaged a 30-day return of +911.4%, establishing a high bar for market outperformance. The rapid-fire accumulation pattern and the sharp stock appreciation since purchase suggest the market has responded favorably, though the fundamental metrics remain a material constraint on baseline valuation.

Janus Henderson (10% owner) bought 220,083 shares at $3.18 avg on ABIO in four transactions for $699,165.11

Janus Henderson executed 4 separate purchases totaling 220,083 shares for $699,165.11 between July 24–25, 2024, at a blended average price of $3.18—representing an 11.6% increase to its holdings at ABIO. This accumulation occurs at prices 21.5% below the 52-week high of $48.00 and follows a sequence of five prior buys at this ticker within days (July 8–11), suggesting sustained acquisition activity. The company remains unprofitable (net income $-2,009,000.00 for the latest quarter and negative full-year earnings), and the stock has declined 9.5% over 30 days and 12.3% over 90 days from the transaction date. The timing context is critical: Janus Henderson's cross-ticker track record shows 9 prior buys, but none of the 5 prior ABIO transactions yet have measurable 90-day outcomes, making it premature to assess execution quality at this specific ticker.

10% Owner Janus Henderson buys 408.8K shares at blended avg $3.49 across 9 transactions in early July 2024

Janus Henderson Group PLC, a 10% owner of ARCA Biopharma, executed 9 separate share purchases totaling 408,777 shares for $1,427,344.99 between July 3–11, 2024, at prices ranging from $3.41 to $3.55 with a blended average price of $3.49. This represents a 27.6% increase in Janus Henderson's stake, from 1,482,535 shares pre-transaction to 1,891,312 shares post-transaction. The purchases occurred when the current stock price stands at $40.20 (16.2% below its 52-week high of $48.00), though the transaction prices themselves occurred when the stock was materially lower. The timing of multiple tranches over a nine-day window and the material increase in ownership concentration by a major institutional stakeholder warrant investor attention in the context of the company's financial condition: ARCA reported zero revenue in its latest quarter and negative net income of $-2,009,000, indicating the company is unprofitable. The scale and systematic nature of this accumulation by a 10% owner should be tracked alongside the company's path to profitability or future capital needs.